Royalty Pharma (RPRX) just unveiled an update.
Servier’s new drug Voranigo has gained FDA approval, promising treatment for patients with a specific type of brain cancer. Under a lucrative deal, Royalty Pharma will pay Agios $905 million for a slice of Voranigo’s future sales, betting on the drug’s success with projected annual sales exceeding $1 billion and generating substantial royalties possibly until 2038. This deal underscores the high stakes and potential rewards in pharmaceutical investments.
For an in-depth examination of RPRX stock, go to TipRanks’ Stock Analysis page.
